- Thyroid cancer diagnostics, encompassing imaging modalities, fine-needle aspiration biopsies, and molecular testing, are increasingly vital components of modern oncology due to their role in early detection, accurate classification, and effective disease monitoring in both hospital and clinical settings
- The escalating demand for thyroid cancer diagnostics is primarily fueled by the rising global incidence of thyroid malignancies, growing awareness of the importance of early diagnosis, and technological advancements in molecular and imaging-based diagnostic tools
- North America dominated the thyroid cancer diagnostics market with the largest revenue share of 39.2% in 2024, driven by advanced healthcare infrastructure, high screening rates, and a robust presence of diagnostic solution providers, with the U.S. experiencing increased uptake of precision diagnostic tools and next-generation sequencing for thyroid nodule assessment
- Asia-Pacific is expected to be the fastest growing region in the thyroid cancer diagnostics market during the forecast period due to improving healthcare access, rising awareness, and government initiatives for cancer screening
- Imaging test segment dominated the thyroid cancer diagnostics market with a market share of 47% in 2024, driven by its non-invasive nature, diagnostic accuracy, and widespread availability in primary and tertiary healthcare settings
